MA44079A - Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine - Google Patents

Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Info

Publication number
MA44079A
MA44079A MA044079A MA44079A MA44079A MA 44079 A MA44079 A MA 44079A MA 044079 A MA044079 A MA 044079A MA 44079 A MA44079 A MA 44079A MA 44079 A MA44079 A MA 44079A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
compositions containing
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
Prior art date
Application number
MA044079A
Other languages
English (en)
Other versions
MA44079B1 (fr
Inventor
Kali Satya Bhujanga Rao Adibhatla
Venkata Satyanarayana Appadwedula
Mitrabhanu Mohanty
Venkaiah Chowdary Nannapaneni
Durga Maheswari Parvataneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA44079A publication Critical patent/MA44079A/fr
Publication of MA44079B1 publication Critical patent/MA44079B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA44079A 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine MA44079B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (fr) 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Publications (2)

Publication Number Publication Date
MA44079A true MA44079A (fr) 2021-04-21
MA44079B1 MA44079B1 (fr) 2021-10-29

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44079A MA44079B1 (fr) 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Country Status (33)

Country Link
US (1) US10383872B2 (fr)
EP (1) EP3389633B1 (fr)
JP (2) JP6896738B2 (fr)
KR (1) KR20180102584A (fr)
CN (1) CN108495620B (fr)
AU (1) AU2016373574B2 (fr)
BR (1) BR112018012458A2 (fr)
CA (1) CA3008634A1 (fr)
CL (1) CL2018001590A1 (fr)
CO (1) CO2018007112A2 (fr)
CY (1) CY1124580T1 (fr)
DK (1) DK3389633T3 (fr)
EA (1) EA036513B1 (fr)
ES (1) ES2881883T3 (fr)
GB (1) GB2564262A (fr)
GE (2) GEP20207176B (fr)
HK (1) HK1254573A1 (fr)
HR (1) HRP20211590T1 (fr)
HU (1) HUE056269T2 (fr)
IL (1) IL260085B (fr)
LT (1) LT3389633T (fr)
MA (1) MA44079B1 (fr)
MX (1) MX374725B (fr)
PH (1) PH12018501292A1 (fr)
PL (1) PL3389633T3 (fr)
PT (1) PT3389633T (fr)
RS (1) RS62422B1 (fr)
SG (1) SG11201805142RA (fr)
SI (1) SI3389633T1 (fr)
SM (1) SMT202100583T1 (fr)
UA (1) UA122592C2 (fr)
WO (1) WO2017103941A1 (fr)
ZA (1) ZA201804203B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN112118830B (zh) * 2018-05-14 2023-11-10 比利时胶囊公司 高活性剂载量的固体剂型
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
AP2470A (en) 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (fr) * 2010-07-02 2012-01-05 富士化学工業株式会社 Dispersion solide de bosentan
GB2488788B (en) 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス,インコーポレーテッド インジルビン固体分散体組成物

Also Published As

Publication number Publication date
WO2017103941A1 (fr) 2017-06-22
PH12018501292A1 (en) 2019-02-04
CN108495620A (zh) 2018-09-04
GEAP202014833A (en) 2020-06-25
US10383872B2 (en) 2019-08-20
HRP20211590T1 (hr) 2022-01-07
ZA201804203B (en) 2020-08-26
IL260085A (en) 2018-07-31
DK3389633T3 (da) 2021-08-30
HUE056269T2 (hu) 2022-02-28
IL260085B (en) 2021-09-30
BR112018012458A2 (pt) 2018-12-18
CY1124580T1 (el) 2022-07-22
ES2881883T3 (es) 2021-11-30
CN108495620B (zh) 2021-09-03
JP2018538325A (ja) 2018-12-27
GB2564262A (en) 2019-01-09
SI3389633T1 (sl) 2021-11-30
CL2018001590A1 (es) 2018-11-30
PL3389633T3 (pl) 2021-12-13
KR20180102584A (ko) 2018-09-17
MA44079B1 (fr) 2021-10-29
PT3389633T (pt) 2021-08-05
AU2016373574B2 (en) 2021-10-14
GB201811142D0 (en) 2018-08-22
GEP20207176B (en) 2020-11-10
JP2021059551A (ja) 2021-04-15
SG11201805142RA (en) 2018-07-30
GEAP201614833A (fr) 2020-06-25
LT3389633T (lt) 2021-09-10
RS62422B1 (sr) 2021-10-29
JP6896738B2 (ja) 2021-06-30
CO2018007112A2 (es) 2018-07-19
EP3389633A4 (fr) 2019-08-07
CA3008634A1 (fr) 2017-06-22
US20190015412A1 (en) 2019-01-17
AU2016373574A1 (en) 2018-07-12
EP3389633B1 (fr) 2021-07-14
MX374725B (es) 2025-03-06
EA201891443A1 (ru) 2019-01-31
EA036513B1 (ru) 2020-11-18
HK1254573A1 (zh) 2019-07-19
UA122592C2 (uk) 2020-12-10
SMT202100583T1 (it) 2021-11-12
EP3389633A1 (fr) 2018-10-24
MX2018007281A (es) 2018-11-29

Similar Documents

Publication Publication Date Title
MA50541A (fr) Formulations pharmaceutiques
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
BR112016023628A2 (pt) composições farmacêuticas.
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3655017T3 (da) Farmaceutisk sammensætning
MA42303A (fr) Formulations pharmaceutiques
DK3529240T3 (da) Farmaceutiske forbindelser
MA46867A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
PL3200772T3 (pl) Kompozycje farmaceutyczne zawierające alpelisyb
ZA201804203B (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
DK3583943T3 (da) Farmaceutisk sammensætning
MA49837A (fr) Compositions pharmaceutiques
EP3383371A4 (fr) Formulation pharmaceutique
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (fr) Formulations pharmaceutiques
DK3728220T3 (da) Farmaceutiske forbindelser
GB201609222D0 (en) Pharmaceutical formulation
DK3601277T3 (da) Farmaceutisk formulering
EP3423041A4 (fr) Compositions pharmaceutiques
EP3528818A4 (fr) Compositions pharmaceutiques
MA49625A (fr) Compositions pharmaceutiques
EP3319596A4 (fr) Compositions pharmaceutiques